Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales.
Steven KerrStuart BedstonDeclan T BradleyMark JoyEmily LowthianRachel M MulhollandAshley AkbariF D Richard HobbsVittal Srinivasa KatikireddiSimon de LusignanIgor RudanFatemeh TorabiRuby S M TsangRonan A LyonsChris RobertsonAziz SheikhPublished in: International journal of epidemiology (2022)
We found strong evidence of waning in VE/rVE for Doses 1 and 2 of ChAdOx1, as well as Dose 1 of BNT162b2. This evidence may be used to inform policies on timings of additional doses of vaccine.